Osteosarcoma — Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants With Advanced Sarcoma (MK-8669-018 AM1)(COMPLETED)
Citation(s)
A Phase II Study of AP23573, An mTOR Inhibitor, in Patients With Advanced Sarcoma